Filing Overview
Galecto, Inc. filed a Form 8-K on December 21, 2023, reporting positive topline results from its Phase 2a MYLOX-1 trial of GB2064 in patients with myelofibrosis. The request metadata identifies Damora Therapeutics, Inc., but the filing names Galecto, Inc. as the registrant.
Business Context and Trial Results
- MYLOX-1 was an open-label, single-arm Phase 2 study in patients who were ineligible, refractory, or intolerant to Janus kinase inhibitor therapy.
- The trial dosed 18 patients with GB2064 monotherapy at 1,000 mg twice daily for nine months.
- Eleven patients, or 61%, had previously received ruxolitinib; eight were refractory and three were intolerant.
- Six of ten evaluable patients treated for at least six months achieved at least a one-grade reduction in bone marrow collagen fibrosis.
- Bone marrow biopsies indicated that GB2064 penetrated the disease compartment, and plasma testing showed systemic target engagement with LOXL2.
- All six patients with at least a one-grade fibrosis reduction had stable hemoglobin, white blood cell, and platelet parameters.
Financial Metrics and Liquidity
The filing does not provide revenue, profit or loss, cash flow, margins, debt, cash balance, liquidity, or other financial statement metrics.
Material Changes and Clinical Outcomes
- At six months, one patient achieved at least a 35% reduction in spleen volume, two patients achieved more than a 50% reduction in Total Symptom Score, and one patient achieved an anemia response.
- Four patients entered the study extension phase based on treating-physician-assessed clinical benefit; one patient had received treatment for more than 30 months.
- Eight patients completed the core treatment phase, while ten discontinued because of an adverse event or disease progression.
Outlook, Risks, and Unusual Items
- GB2064 was described as generally tolerable. The most common treatment-related adverse events were gastrointestinal and were generally manageable with standard therapy.
- The only treatment-related serious adverse event was a fall, assessed by the investigator as possibly related to GB2064.
- Galecto stated that it would not decide whether to fund additional GB2064 trials until completion of its previously announced strategic alternatives process.
- The results are from an open-label, single-arm trial with a small patient population; the filing does not provide comparative efficacy data or confirmatory evidence of clinical benefit.
Key Facts to Verify
- Confirm the registrant identity, because the filing names Galecto, Inc., while the request metadata names Damora Therapeutics, Inc.
- Verify the denominator and follow-up underlying the reported six-of-ten fibrosis response.
- Assess the full safety dataset, including the ten discontinuations and the reasons for each discontinuation.
- Review the strategic alternatives process and any resulting decision regarding further GB2064 development.
- Verify whether subsequent filings provide financial metrics, funding capacity, or additional clinical data not included in this Form 8-K.